SH3GLB2

Across TCGA pan-cancer cohorts, SH3GLB2 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of SH3GLB2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SH3GLB2 RNA is repressed in tumor relative to normal tissue. In most cancer types SH3GLB2 is over-expressed in tumor, although a few such as KIRC and LUAD show the opposite, repressed pattern.

KIRC, LIHC, and COAD are the cancer types where SH3GLB2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SH3GLB2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.877	<.001	12	view →
LIHC	Female	II,III,IV	+1.204	<.001	9	view →
COAD	All	IV	+0.882	<.001	8	view →
THCA	Male	All	+0.385	<.001	8	view →
LUAD	Female	All	−0.316	<.001	7	view →
CHOL	All	All	+2.655	<.001	5	view →
HNSC	All	II,III,IV	−0.323	.018	4	view →
KIRP	All	All	−0.546	.003	2	view →
KICH	Male	All	−0.593	.020	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

SH3GLB2–KIRC

Open the KIRC breakdown →